Yuki Oba

Yuki Oba

Auto-generated profile, based on publicly available information

Yuki Oba

Nephrology Center and Department of Rheumatology, Toranomon Hospital Kajigaya , Kanagawa

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 July 2024 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
YYYusuke Yoshimura
Yusuke Yoshimura
MYMasayuki Yamanouchi
Masayuki Yamanouchi
HMHiroki Mizuno
Hiroki Mizuno
DIDaisuke Ikuma
Daisuke Ikuma
RKRyo Koizumi
Ryo Koizumi
NSNaoki Sawa
Naoki Sawa
Objective To evaluate the efficacy and safety of first-line biological disease-modifying antirheumatic drugs (bDMARDs) in patients with rheumatoid arthritis (RA) with chronic kidney disease (CKD), including those undergoing haemodialysis (HD). Methods This retrospective cohort study included 425 patients with RA prescribed their first bDMARDs at two hospitals from 2004 to 2021. Patients were categorised by kidney function and bDMARD modality (TNFα inhibitors (TNFαis), interleukin-6 inhibitors (IL-6is), cytotoxic T-lymphocyte antigen-4 immunoglobulin (CTLA4-Ig)). The primary outcome was the 36-month drug retention rate, with secondary outcomes including changes in Disease Activity Score 28 (DAS28)-C reactive protein (CRP)/erythrocyte sedimentation rate (ESR), prednisolone dosage and reasons for discontinuation. Results The 36-month drug retention rates by estimated glomerular filtration rate (eGFR) (≥60, 30–60, <30 mL/min/1.73 m2) were as follows: all bDMARDs (45.2%, 32.0%, 41.4%), TNFαis (45.3%, 28.2%, 34.0%), IL-6is (47.4%, 66.7%, 71.4%) and CTLA-4Ig (50.0%, 31.3%, 33.3%). Even in groups with lower kidney function, the drug retention rate of bDMARDs was generally maintained. However, the retention rate of TNFαis was significantly lower in patients with eGFR <30 mL/min/1.73 m2. IL-6is showed the highest retention rate and the lowest discontinuation rate due to ineffectiveness in this group (HR 0.11, 95% CI 0.02 to 0.85, p=0.03). All bDMARDs improved DAS28-CRP/ESR and reduced prednisolone dosage across all groups. Conclusion bDMARDs demonstrated effective and safe profiles in patients with RA with CKD, even among patients on HD. In particular, IL-6is had a significantly higher drug retention rate in patients with an eGFR of <30 mL/min/1.73 m2 and fewer discontinuations due to ineffectiveness. IL-6is were more efficacious as monotherapy compared with the other bDMARDs.

18 June 2024 in Clinical Kidney Journal
Verified
Journal Article
Open access
PDF file
MYMasatoshi Yoshimoto
Masatoshi Yoshimoto
ASAKINARI SEKINE
AKINARI SEKINE
TSTatsuya Suwabe
Tatsuya Suwabe
YOYuki Oba
Yuki Oba
HMHiroki Mizuno
Hiroki Mizuno
TWTakehiko Wada
Takehiko Wada
Introduction: The DAPA-CKD study showed a protective effect of dapagliflozin on kidney function in chronic kidney disease (CKD) patients with and without diabetes mellitus. Although dapagliflozin is expected to be effective also in CKD patients with autosomal dominant polycystic kidney disease (ADPKD), its efficacy and safety in this population remain unknown because ADPKD was an exclusion criterion in the DAPA-CKD study. Therefore, we evaluated the effects of dapagliflozin in CKD patients with ADPKD. Methods: We performed a retrospective observational study of seven patients with ADPKD treated with dapagliflozin at Toranomon Hospital, Tokyo, Japan. We analyzed changes in estimated glomerular filtration rate (eGFR) slope and annual height-corrected total kidney volume before and after starting dapagliflozin treatment. Results: The median observation period after starting dapagliflozin was 20 months. Four patients received concomitant tolvaptan. The eGFR slope before and after initiation of dapagliflozin could be calculated in six patients and improved in all of them except the one who did not receive a renin-angiotensin system (RAS) inhibitor. Annual height-corrected total kidney volume increased in all patients. Concurrent tolvaptan treatment had no effect. Conclusion: In CKD patients with ADPKD, dapagliflozin may increase kidney volume but may have a protective effect on kidney function when used concomitantly with RAS inhibitors.

20 January 2023 in Mayo Clinic Proceedings: Innovations, Quality & Outcomes
Verified
Journal Article
Open access
TSTatsuya Suwabe
Tatsuya Suwabe
YUYoshifumi Ubara
Yoshifumi Ubara
YOYuki Oba
Yuki Oba
HMHiroki Mizuno
Hiroki Mizuno
DIDaisuke Ikuma
Daisuke Ikuma
NSNaoki Sawa
Naoki Sawa
To examine the changes in total kidney volume (TKV) and total liver volume (TLV) before and after dialysis initiation in patients with autosomal dominant polycystic kidney disease. This was a retrospective, single-center cohort study to investigate the changes in TKV and TLV before and after dialysis initiation, along with influencing factors, using linear mixed models. We enrolled 95 patients with autosomal dominant polycystic kidney disease (85 receiving hemodialysis [HD] and 10 receiving peritoneal dialysis [PD]) who began receiving dialysis at Toranomon Hospital from January 1, 2008, to December 31, 2020. The least squares mean TKV ratio (TKV at each time point/TKV at dialysis initiation) was 63.8% (95% confidence interval [CI], 54.7%-72.9%) at 6 years before dialysis initiation and 95.5% (95% CI, 82.9%-108.2%) at 6 years after dialysis initiation (P<.001). A multivariate linear mixed model analysis revealed that dialysis style (HD or PD) had the strongest effect on changes in TKV (P=.002). The least squares mean TLV ratio was 98.2% (95% CI, 88.4%-108.0%) at 6 years before dialysis initiation and 95.7% (95% CI, 85.2%-106.2%) at 6 years after dialysis initiation (P=.01). Although PD did not have significant effects on changes in TLV (P=.27), the changes in TLV were greater in patients on PD than in those on HD. The TKV increased until dialysis initiation and generally decreased after dialysis initiation. The TLV continued to increase even after dialysis initiation, however, changes in the TLV significantly decreased after dialysis initiation. The increases in TKV and TLV were greater in patients on PD than in those on HD.

30 April 2024 in Clinical Kidney Journal
Verified
Journal Article
Open access
PDF file
YYYusuke Yoshimura
Yusuke Yoshimura
HMHiroki Mizuno
Hiroki Mizuno
DIDaisuke Ikuma
Daisuke Ikuma
MYMasayuki Yamanouchi
Masayuki Yamanouchi
ASAKINARI SEKINE
AKINARI SEKINE
NSNaoki Sawa
Naoki Sawa
Introduction: This study aimed to analyze the clinical course of TAFRO syndrome in patients through extended follow-up, focusing on recurrent cases and long-term remission. Methods: This was a retrospective case series study. We assessed the clinical course of patients diagnosed with TAFRO syndrome between January 2012 and September 2022 at Toranomon Hospital or Toranomon Hospital Kajigaya, excluding those patients who died during the initial hospitalization. Results: Twelve patients were included. Baseline characteristics, laboratory findings, treatment modalities, and outcomes were assessed. During the median follow-up period of 1474 days, two patients experienced recurrence following a reduction in tocilizumab (TCZ) dose, whereas two achieved remission for >400 days without TCZ treatment. The remaining eight patients maintained remission under the continued TCZ therapy. Recurrence diagnosis was complicated by the non-simultaneous presentation of the five manifestations of TAFRO syndrome. The patients who experienced recurrence showed milder manifestations and faster recovery than the initial onset. Glomerular endotheliopathy was evident in kidney biopsies during recurrence, which was similar to the initial presentation. In a case where only inflammation preceded other manifestation, a kidney biopsy was pivotal in distinguishing TAFRO syndrome relapse from other inflammatory conditions such as infection. Pretreatment serum IL-6 levels were within the reference range only in patients who experienced long-term remission without TCZ treatment. Conclusions: This is the first study to perform kidney biopsies on recurrent TAFRO cases, highlighting recurrence after TCZ dosage reduction, non-simultaneous manifestation of symptoms, the utility of kidney biopsies in recurrence diagnosis, and potential non-IL-6 pathogenesis factors. Pretreatment serum IL-6 levels may help identify patients suitable for maintenance therapy without TCZ. Further investigation is warranted to identify stratified treatment approaches based on individual etiologic factors.

25 January 2025 in Rheumatology
Verified
Journal Article
Closed access
YYYusuke Yoshimura
Yusuke Yoshimura
MYMasayuki Yamanouchi
Masayuki Yamanouchi
RKRyo Koizumi
Ryo Koizumi
HMHiroki Mizuno
Hiroki Mizuno
YOYuki Oba
Yuki Oba
NSNaoki Sawa
Naoki Sawa
Objectives: To evaluate the efficacy and safety of first-line targeted synthetic DMARDs (tsDMARDs) in patients with RA and chronic kidney disease (CKD). Methods: This retrospective cohort study included 216 patients with RA prescribed their first tsDMARDs at two hospitals between 2013 and 2022. Dose reduction and contraindication guidelines for tsDMARDs according to kidney function were followed. The patients were categorized by kidney function and tsDMARD modality. The primary outcome was the 24-month drug retention rate, and the secondary outcomes were changes in the Disease Activity Score 28-CRP (DAS28-CRP) level, prednisolone dosage and reasons for discontinuation. Results: The 24-month drug retention rates according to the estimated glomerular filtration rate (eGFR) (≥60%, 30–60% or <30 ml/min/1.73 m2) were as follows: all tsDMARDs (46.0%, 44.1%, 47.1%), tofacitinib (55.9%, 53.3%, 66.7%), baricitinib (64.2%, 42.0%) and peficitinib (36.4%, 44.1%, 40.0%). Even in groups with lower kidney function, the drug retention rate was maintained (adjusted hazard ratio was 1.14 [95% confidence interval, 0.81–1.62], P = 0.45). Patients had a decreased DAS28-CRP (P < 0.01) and a reduced prednisolone dosage (P < 0.01) over the six-month period following tsDMARD initiation. The incidence of herpes zoster and deep vein thrombosis (DVT) was higher in the group with an eGFR <30 ml/min/1.73 m2, but not statistically significant. Conclusions: tsDMARDs have demonstrated efficacy and safety in patients with RA and CKD; however, clinicians should consider the potential for herpes zoster and DVT in patients with eGFR <30 ml/min/1.73 m2.

1 March 2021 in Kidney Medicine
Verified
Journal Article
Open access
YOYuki Oba
Yuki Oba
NSNaoki Sawa
Naoki Sawa
HMHiroki Mizuno
Hiroki Mizuno
JHJunichi Hoshino
Junichi Hoshino
KKKeiichi Kinowaki
Keiichi Kinowaki
YUYoshifumi Ubara
Yoshifumi Ubara
Autosomal dominant tubulointerstitial kidney disease subtype hepatocyte nuclear factor 1β (ADTKD-HNF1B) is a hereditary disease caused by variants of HNF1B that is characterized by a family history of tubulointerstitial nephropathy with concomitant diabetes mellitus. We report on a Japanese man in his early 40s who had ADTKD-HNF1B diagnosed. He had a reduced glomerular filtration rate, borderline diabetes mellitus, multiple small cysts in his bilateral kidneys, and pancreatic hypoplasia. He also had a family history of diabetes and kidney cystic lesions. These phenotypes represent ADTKD-HNF1B and genetic analysis revealed a missense variant of HNF1B. Kidney biopsy demonstrated not only tubulointerstitial fibrosis but also abnormal mitochondrial morphology in tubular cells, a novel finding.